Why the study?
Does discontinuation of antiplatelet therapy during anticoagulation therapy increase the risk of very late stent thrombosis in patients with peri-stent contrast staining?
Does discontinuation of antiplatelet therapy during anticoagulation therapy increase the risk of very late stent thrombosis in patients with peri-stent contrast staining?
Discontinuation of antiplatelet therapy in patients requiring anticoagulation who have peri-stent contrast staining may lead to very late stent thrombosis, suggesting a need for individualized antithrombotic strategies.
May warrant caution discontinuing antiplatelet therapy during anticoagulation with peri-stent contrast staining; leaves open optimal regimens.
A 54-year-old man was admitted to our hospital due to intermittent chest pain. He had a history of acute myocardial infarction, and peri-stent contrast staining had been observed at the stent implantation site. The patient previously underwent anticoagulation therapy for left ventricular thrombus and antiplatelet therapy to prevent stent thrombosis. More than one year after implantation of a drug-eluting stent, antiplatelet drugs were discontinued, and anticoagulant alone was prescribed according to the guidelines, which resulted in very late stent thrombosis. The risks of both bleeding and thrombosis must be fully considered when deciding whether or not to discontinue antiplatelet therapy during anticoagulation therapy.
No takes yet. Share an insight, caveat, or question.
Endo et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: